SNS funded Dymista® with a retail price of €15.61, which will expand access to this first-line treatment and thus control nasal and ocular symptoms in people suffering from allergic rhinitis.
Allergic rhinitis is a pathology that causes inflammation of the nasal mucosa, which is the most common allergic disease in our country. It affects more than 20% of the Spanish population, especially young people, with pollen and dust mites being the most common causes.2. Allergist Dr. Juan Manuel Igea explained that “the incidence of this type of rhinitis is very high in Western countries due to our lifestyle. The absence of infections, antibiotics, diets or environmental pollution leads to a significant increase in the number of allergic diseases. Every year”.
The rise of allergic diseases and their consequences
According to the Primary Health Care Clinical Database, the number of patients with allergies in Spain increased by 42% between 2016 and 2021.3. In particular, studies conducted by Spanish allergists show, according to confirmed by Dr. Juan Manuel Igea, What “the most frequent cases are associated with cases of allergic rhinitis, since this is a chronic disease that affects a significant part of the population.“.
In this sense, SEORL estimates that the global prevalence of allergic rhinitis is between 20 and 40%.4, which is manifested mainly by sneezing, lacrimation, runny nose and complete or partial loss of smell. The factors causing the appearance of this pathology are numerous and are still under study. However, the lifestyle of Western societies is one of the main factors given that limited exposure to natural allergens due to the urban environment can affect the strength of the immune system and contribute to the development of allergic rhinitis. In addition, environmental pollution contributes to the spread of allergens.
The lifestyle of the Western world has negative consequences, especially for people with a genetic predisposition to allergic diseases. These people successively develop various pathologies that build their own atopic march, in which dermatitis often occurs first, followed by allergies to certain foods, rhinitis and, later, asthma.
The consequences of this type of rhinitis greatly affect our daily lives. According to Igea, “The quality of life declines much more with allergic rhinitis than with other more serious diseases such as diabetes. The inability to breathe normally during the day, nasal congestion or headache make this disease very unpleasant.”
Therefore, it is extremely important to apply adequate treatment to stop its development. Regarding this issue, Dr. Juan Manuel Igea emphasizes that “if left untreated and the disease progresses, we can have many infectious complications, such as bronchitis or sinusitis. We now have very safe and effective drugs to fight allergic rhinitis and prevent it from developing into other, more serious conditions like asthma.”
Benefits of Dimista® in the treatment of allergic rhinitis
The use of Dimista® is associated with an improvement in the symptoms of allergic rhinitis and asthma, two diseases whose symptoms correlate, therefore, a complex therapeutic approach is recommended. Dymista® meets the real needs of patients with allergic rhinitis and allows effective control of symptoms throughout the year. In addition, the treatment has been shown to improve asthma control and reduce the need for patients to use emergency medications.5.
The drug is more effective than intranasal corticosteroids (INS) in monotherapy. We act quickly, the result is already in 5 minutes6. The product has been clinically tested in studies involving more than 4,600 patients.
A real study conducted on patients with allergic rhinitis from 7 European countries.7 associated the use of MP-AzeFlu (Dymista®) with high levels of efficacy, comfort and patient satisfaction. 70% of respondents stated that they were more or much more satisfied with Dymista® than they were with previous allergic rhinitis treatments. Similarly, 57% of participants noted an improvement in their quality of life.
Data sheet Dimista®: 76618_ft.pdf (aemps.es)
perspective Dimista®: .:: TOP ::. DYMISTA 137 µg/50 µg/Nasal Spray Leaflet Suspension (aamps.es)
Fountain: Cicero Communication
Recommendations:
1. Canonica GW et al. The burden of allergic rhinitis and the impact of MP-AzeFlu from a patient perspective: a pan-European patient survey. Curr Med Res Opin. 2021;37(7):1259-72.
2. Spanish Society of Family and Community Medicine. https://www.semfyc.es/rinitis-alergica-10-motivos-de-consulta-mas-frecuentes-en-atencion-primaria/
3. 2Respiratory_infections.pdf (sanidad.gob.es)
4. https://seorl.net/rinitis-alergica-diagnostico/
5. PriceD et al. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu for the treatment of multimorbid allergic rhinitis and asthma. Clean Mol Allergy. 2020; 18:15.
6. Busquet, J. et al. Onset of action of intranasal fixed combination azelastine-fluticasone propionate in an allergen chamber. J Allergy Clinic Immunol Pract. 2018 ;6(5):1726-32.e6.
7. Canonica GW et al. The burden of allergic rhinitis and the impact of MP-AzeFlu from a patient perspective: a pan-European patient survey. Curr Med Res Opin. 2021;37(7):1259-72.